Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
ObjectiveThis study aimed to determine and compare the tumor shrinkage rate and its durability by enfortumab vedotin treatment between primary urothelial carcinoma and metastatic organs.MethodsWe retrospectively evaluated the tumor shrinkage rate in 39 Japanese patients treated with enfortumab vedot...
Saved in:
Main Authors: | Daiki Ikarashi, Tatsuya Kawamura, Keita Ogasawara, Yumeka Arakawa, Arisa Machida, Ayato Ito, Ei Shiomi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Jun Sugimura, Wataru Obara |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1493922/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
by: Toshiki Kijima, et al.
Published: (2025-01-01) -
Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis
by: Takafumi Yanagisawa, et al.
Published: (2025-02-01) -
Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
by: Weiming Liang, et al.
Published: (2025-02-01) -
Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects
by: Yufei Wang, et al.
Published: (2025-02-01) -
A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
by: Shuailei Dong, et al.
Published: (2025-01-01)